Results 1 to 10 of about 3,140 (170)

A Unique Hairy Cell Leukemia Variant [PDF]

open access: yesCase Reports in Oncology, 2016
A 65-year-old woman presented with easy bruising, left upper quadrant pain, decreased appetite, and weight loss. She had splenomegaly and lymphocytosis (lymphocyte count of 11.6 × 109/l), with remarkably abnormal appearing morphology.
Charles Jian, Cyrus C. Hsia
doaj   +5 more sources

Variant form of hairy cell leukemia [PDF]

open access: yesClinical Case Reports, 2019
Mature lymphoid B‐cell proliferations with hairy cells represent heterogeneous entities where specific diagnosis is difficult but important since it impacts therapeutic management.
Margaux Wiber   +5 more
doaj   +6 more sources

Obinutuzumab combined with bendamustine for the treatment of hairy cell leukemia variant: a case report and literature review [PDF]

open access: yesFrontiers in Oncology
Hairy cell leukemia variant (HCL-v) is a rare and more aggressive subtype of B-cell leukemia. While it shares certain clinical features with classical hairy cell leukemia (HCL-c), HCL-v typically follows a more malignant course and responds poorly to ...
Junjun Bai   +10 more
doaj   +4 more sources

Hairy cell leukemia variant: the importance of differential diagnosis [PDF]

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2015
Hairy cell leukemia is a rare disease comprising about 2% of lymphoid neoplasms.1 This neoplasm can be confused with other hematologic diseases. Therefore, a differential diagnosis must be performed between classic hairy cell leukemia, hairy cell leukemia variant, and splenic marginal zone lymphoma (SMZL).2 According to the World Health Organization ...
Renata Cristina Messores Rudolf-Oliveira   +4 more
doaj   +4 more sources

Cell therapy for a rare disease- hairy cell leukemia variant [PDF]

open access: yesOncoImmunology
Hairy cell leukemia variant (HCL-v) is a rare malignancy of clonal mature B-cells that follows a chronic disease course. HCL-v patients are often resistant to purine nucleoside analogs, which are the first-line therapy.
Claire Fritz   +5 more
doaj   +4 more sources

Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. [PDF]

open access: yesLeuk Res, 2013
Hairy cell leukemia (HCL) and hairy cell leukemia-variant (HCL-v) are rare diseases with overlapping clinico-pathological features. We performed flow cytometry analysis (FCM) of 213 cases (169 HCL, 35 HCL-v, 9 splenic marginal zone lymphoma (SMZL)), correlating results with available corresponding clinical and morphological data.
Shao H   +6 more
europepmc   +5 more sources

B Cell Activating Factor Induces Drug Resistance in Hairy Cell Leukemia Variant [PDF]

open access: yesBiomedicines
Background: Chemoresistance is an existing challenge faced in the treatment of the hairy cell leukemia variant (HCL-v). Classical hairy cell leukemia (HCL-c) is very sensitive to the standard of care with purine nucleoside analogs (PNAs) cladribine (cDa)
Claire Fritz   +7 more
doaj   +2 more sources

Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib

open access: yesTherapeutic Advances in Hematology, 2022
Hairy cell leukemia (HCL) and HCL-like disorders such as hairy cell leukemia variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL) are rare indolent B-cell malignancies.
Jérôme Paillassa   +2 more
doaj   +2 more sources

Toxoplasmic Encephalitis with Untreated Hairy Cell Leukemia Variant. [PDF]

open access: yesIntern Med, 2016
Toxoplasmic encephalitis is a rare infectious complication in patients with hematological malignancy except for allogeneic hematopoietic stem cell transplantation (HSCT). We herein report a case of possible toxoplasmic encephalitis with untreated hairy cell leukemia variant.
Ikebe T   +7 more
europepmc   +4 more sources

Polycythemia vera followed by hairy cell leukemia variant [PDF]

open access: yesBlood, 2012
![Figure][1] A 59-year-old female was diagnosed 13 years earlier with JAK2 617-positive polycythemia vera (PV) and treated with phlebotomies. Recently she developed progressive splenomegaly and decreased needs for phlebotomy.
Kotchetkov Rouslan
exaly   +3 more sources

Home - About - Disclaimer - Privacy